Whole blood, serum, plasma drug assay kit, 50 ng/mL

In contemporary scientific research—spanning pharmacology, toxicology, neuroscience, and translational medicine—accurate quantification of drug concentrations in biological matrices (whole blood, serum, plasma) is a foundational requirement for validating experimental hypotheses, interpreting pharmacokinetic (PK)/pharmacodynamic (PD) relationships, and ensuring the reproducibility of preclinical and clinical research data. Traditional drug detection approaches, such as high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) or gas chromatography-mass spectrometry (GC-MS), while highly specific, present significant barriers for many research teams: they require substantial upfront investment in specialized equipment, demand advanced technical expertise for operation and data analysis, and often involve time-consuming sample pretreatment (e.g., solid-phase extraction, derivatization)—limiting their accessibility for small to mid-sized laboratories, academic research groups, or projects with high sample throughput needs.

Against this research-focused backdrop, specialized bioanalytical kits tailored to streamline drug quantification in complex biological samples have emerged as critical tools for accelerating scientific discovery. Our Whole Blood, Serum, Plasma Drug Assay Kit (Cat.No: CD-00140) is engineered to address the unique pain points of research users, with a focus on solving challenges that directly impact experimental efficiency and data reliability:

Matrix Interference in Research Samples: Unlike controlled clinical samples, research specimens (e.g., from animal models like mice, rats, or non-human primates) often contain variable levels of interfering substances—including proteins, lipids, and endogenous metabolites—that can skew detection results. Conventional kits may require additional purification steps (e.g., protein precipitation with acetonitrile or methanol) to mitigate this, which not only increases workflow time but also raises the risk of sample loss—critical when research samples are scarce (e.g., from small animal models or limited human cohorts).
Sensitivity for Low-Dose Research Paradigms: Many cutting-edge research studies (e.g., investigations of targeted therapeutics, microdose PK studies, or drug-drug interaction analyses) require detection of drug concentrations at trace levels (often below 100 ng/mL). Entry-level assay kits on the market frequently fail to meet this threshold, leading to incomplete data sets or the inability to detect subtle concentration changes that are key to understanding drug efficacy or toxicity.
Reproducibility Across Research Teams: A core principle of scientific research is data reproducibility. Traditional detection methods are prone to variability due to differences in equipment calibration, operator technique, or reagent batch—making it difficult for research teams to replicate results across laboratories or validate findings in collaborative studies.

This kit integrates research-grade immunoassay technology (aligned with industry standards for preclinical and translational research) to achieve a detection limit of 50 ng/mL, directly addressing the needs of diverse research applications:

Preclinical Pharmacokinetic (PK) Studies: Enables quantification of drug concentrations in rodent, canine, or non-human primate whole blood, serum, or plasma—providing critical data on drug absorption, distribution, metabolism, and excretion (ADME) to guide formulation optimization and dose selection for subsequent clinical trials.
Toxicology Research: Supports in vitro and in vivo toxicology studies by measuring drug accumulation in biological matrices, helping researchers identify dose-dependent toxicity thresholds and assess the safety profile of novel compounds.
Neuroscience and Psychopharmacology Research: Facilitates studies on central nervous system (CNS) drugs by quantifying peripheral drug concentrations (in blood/serum/plasma) that correlate with CNS penetration, aiding in the understanding of drug efficacy in models of neurological disorders (e.g., epilepsy, Parkinson’s disease).
Translational Medicine: Bridges preclinical and clinical research by providing a consistent, reliable tool for quantifying drug concentrations across animal models and early-phase human clinical samples—ensuring that data from preclinical studies can be effectively translated to human applications.